A compound of formula (I) which is an agonist at the adenosine A1 receptor
wherein R2 represents C1-3alkyl, halogen or hydrogen;
R3 represents a fluorinated straight or branched alkyl group of 1-6 carbon atoms; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof.
Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof
申请人:Shanghai SIMR Biotech Co., Ltd.
公开号:US11220503B2
公开(公告)日:2022-01-11
The present invention provides a compound of formula I, a cis-trans isomer, an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, or a pharmaceutical acceptable salt and ester thereof, a preparation method for preparing the same, a pharmaceutical composition comprising the same and a use of the compound as an α5-GABAA receptor regulator, wherein T, Z, A and Y are as defined in the description.
本发明提供了一种式 I 的化合物、顺反异构体、对映体、非对映异构体、外消旋体、溶解物、水合物或其药物可接受盐和酯,制备方法,包含该化合物的药物组合物,以及该化合物作为 α5-GABAA 受体调节剂的用途,其中 T、Z、A 和 Y 如描述中所定义。
[EN] PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF<br/>[FR] DÉRIVÉ DE PHTHALAZINE ET PROCÉDÉ DE PRÉPARATION, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉES<br/>[ZH] 呔嗪类衍生物、其制备方法、药物组合物和用途
Chemoenzymatic syntheses of both enantiomers of cis- and trans-2-aminocyclopentanol as well as cis- and trans-2-aminocyclohexanol, which are valuable building blocks for a plethora of ligands and pharmaceuticals have been efficiently carried out. The strategy involves the stereospecific syntheses of racemic aminocycloalkanol precursors via tagging of a phthalimide as a masking group and subsequent lipase-catalyzed kinetic resolution. Most of the lipases exhibited excellent enantioselectivity (E >> 200) in the transesterification reactions of trans-derivatives, with both N-protected (R,R)-amino acetates and (S,S)-amino alcohols being isolated in enantiopure form. With regard to cis-derivatives, lipases were also very selective, even though the biotransformations were significantly slower. (C) 2013 Elsevier Ltd. All rights reserved.